Investor relations
With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.
We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.
Press Releases
Sedana Medical has carried out a directed share issue raising gross proceeds of 615 MSEK
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INT…
Sedana Medical announces intention to carry out a directed share issue of approximately 600 MSEK
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INT…
Sedana Medical submits IND for US clinical trials
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an In…
Financial Calendar
| SEB NORDIC Healthcare Seminar | 18 January 2022 | 11:20 |
| Year-End report 2021 | 17 February 2022 | 07:00 |
